Sun Pharma ends development of SCD-044 after phase 2 trials fail to meet primary endpoints
SCD-044 trials for psoriasis and atopic dermatitis show no major safety concerns
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.